The MMRF Blog - Multiple Myeloma Research Foundation

The MMRF Blog

Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.

Shah JJ, Jakubowiak AJ, O'Connor OA, Orlowski RZ, Harvey RD, Smith MR, Lebovic D, Diefenbach C, Kelly K, Hua Z, Berger AJ, Mulligan G, Faessel HM, Tirrell S, Dezube BJ, Lonial S. Clin Cancer Res. 2015 Nov 11. [Epub ahead of print] PMID: 26561559 [PubMed - as supplied by publisher] READ MORE

Posted: November 19, 2015

Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study.

Muchtar E, Gatt ME, Rouvio O, Ganzel C, Chubar E, Suriu C, Tadmor T, Shevetz O, Lavi N, Shochat T, Cohen YC, Avivi I, Raanani P, Magen H. Br J Haematol. 2015 Nov 16. doi: 10.1111/bjh.13799. [Epub ahead of print] PMID: 26567759 [PubMed - as supplied by publisher] READ MORE

Posted: November 19, 2015

Statement from Walter M. Capone, President and CEO of the Multiple Myeloma Research Foundation Regarding the Decision by the U.S. Food and Drug Administration (FDA) to Approve Darzalex® (daratumumab) as a treatment for patients with multiple myeloma

“The approval of daratumumab brings another promising advance in the therapeutic landscape for patients with significant unmet needs. The MMRF is proud to partner Janssen in the development of such treatments and we hope to continue to achieve great strides in the treatment of people living multiple myeloma..." READ MORE

Posted: November 16, 2015

Page 41 of 87« First...102030...3940414243...506070...Last »